Mauna Kea Technologies Announces Breakthrough Positive Clinical Results in Lung Cancer Obtained with Cellvizio Page 1

Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT)the inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the publication¹ in the peer-reviewed Journal of Thoracic Diseases of new breakthrough clinical results demonstrating the efficacy of its needle-based Confocal Laser Endomicroscopy (nCLE) technology for the characterization of peripheral lung cancer and preparation for surgical resection.

This study, conducted by Professor Stéphane Renaud’s team at Nancy University Hospital, evaluated the use of Cellvizio’s nCLE platform in combination with electromagnetic navigation bronchoscopy (ENB) to characterize suspicious lung nodules and prepare them for surgical resection if necessary. The results highlight the potential of nCLE to rapidly and accurately identify malignant lesions, while minimizing the risks associated with traditional diagnostic methods, including ionizing radiation.